Cboe UK DKK

ALK-Abelló A/S (ALKBC.XC)

146.60

0.00

(0.00%)

At close: April 24 at 12:01:25 PM GMT+1

ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians

Agreement builds on landmark licensing deal between ARS Pharma and ALK-Abelló A/S, which provided ARS Pharma with $145 million upfront and ALK with commercialization rights to neffy in Canada, United Kingdom, European Union and certain other countries outside the United States New partnership expands ARS Pharma’s direct promotional efforts to nearly 20,000 healthcare providers, reaching key pediatricians ahead of the back-to-school season SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceu

GlobeNewswire 19 hours ago

AKBLF

SPRY
ALK enters into neffy® co-promotion agreement in the USA

Co-promotion with ARS Pharma based on cost sharing and performance-based revenue sharing.ALK to accelerate build-up of its US paediatric sales channel in a balanced way. Agreement does not change ALK’s revenue and earnings outlook for 2025. ALK (ALKB.DC / OMX: ALK B) today announced a 4-year agreement with US-based ARS Pharmaceuticals, Inc. (“ARS Pharma”, NASDAQ: SPRY) to co-promote the neffy® adrenaline (epinephrine) nasal spray to up to 9,000 named paediatricians in the USA. These paediatricia

GlobeNewswire 19 hours ago

AKBLF
Invitation to the presentation of ALK’s first quarter 2025 results on Tuesday, 6 May 2025

ALK (ALKB.DC / OMX: ALK B) will publish its results for the first quarter of 2025 in the morning on Tuesday, 6 May 2025. Later on the same day, the company will host a presentation for investors and analysts at 11:00 a.m. CEST, where ALK’s management will comment on the results and outlook and be available for questions. ALK will be represented by Peter Halling, President & CEO, Claus Steensen Sølje, CFO and Per Plotnikof, VP, Head of IR. Live audio webcast The meeting will be audio webcasted li

GlobeNewswire 3 days ago

AKBLF
ITULAZAX® tree pollen tablet approved for treatment of children in Europe

ALK (ALKB.DC / OMX: ALK B) today announced that its European regulatory filing for ITULAZAX® (tree pollen sublingual allergy immunotherapy tablet) for treatment of young children and adolescents aged five to 17 has been approved by the health authorities in 17 EU countries via a type II variation procedure. First market introductions are expected to follow in the coming months ahead of the 2025/2026 initiation season for new patients starting treatment on pollen allergy tablets. Executive Vice P

GlobeNewswire 9 days ago

AKBLF
Grant of share-based long-term incentive instruments to members of the Board of Management and key employees

ALK (ALKB:DC / OMX: ALK B / AKBLF): According to the company’s remuneration policy adopted at the company's Annual General Meeting on 14 March 2024 and in line with the company’s usual practice, the Board of Directors has passed a resolution to grant up to a total of 250,000 share-based instruments for the purpose of the company’s long-term incentive plan (LTIP) for the Board of Management and key employees for 2025. The objectives of the LTIP are to incentivise and reward long-term value creati

GlobeNewswire 29 days ago

AKBLF
Annual General Meeting in ALK-Abelló A/S held on 13 March 2025

ALK (ALKB:DC / OMX: ALK B / AKBLF): ALK-Abelló A/S held its Annual General Meeting on 13 March 2025. The Annual General Meeting transacted the following business: Approval of the annual report 2024 and discharge of the Board of Directors and Board of ManagementResolution not to declare ordinary dividend in accordance with the approved annual report for 2024 and to allocate the profits in accordance with the approved annual reportAdoption of the remuneration report for 2024Adoption of the remuner

GlobeNewswire last month

AKBLF
ACARIZAX® approved in Canada for treatment of young children

ALK (ALKB:DC / OMX: ALK B) today announced that Health Canada has approved ALK’s ACARIZAX® tablet for use in children, aged five to 11, with house dust mite (HDM) allergy. ACARIZAX® is now indicated for treatment of moderate to severe HDM-induced allergic rhinitis, with or without conjunctivitis, in children, adolescents, and adults in Canada aged five to 65. Outside Europe, Canada is one of the most important markets for ALK’s respiratory tablet portfolio with sales growing continuously by doub

GlobeNewswire last month

AKBLF
Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the following transactions by managerial staff: The Board of Directors has previously granted share options and performance shares in ALK-Abelló A/S, re. company release no. 07/2022 of 24 March 2022. The right to share options and performance shares may be achieved in March 2025, provided that ALK achi

GlobeNewswire last month

AKBLF
U.S. FDA Approves Label Expansion for ALK's ODACTRA® (House Dust Mite Allergen Tablet) for Sublingual Use as Immunotherapy to Now Include Children with House Dust Mite Allergy

ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the U.S. Food and Drug Administration (FDA) expanded its indication of ODACTRA® (House Dust Mite Allergen Tablet) for the treatment of house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, to now include children ages 5 through 11 years, in addition to patients 12 through 65 years of age.2 ODACTRA is an allergy immunotherapy indicated to treat HDM-induced allergic rhinitis and is administered sublingually as a sma

PR Newswire 2 months ago

AKBLF
FDA approves ODACTRA® for the treatment of house dust mite allergy in young children

ALK (ALKB:DC / OMX: ALK B) today announced that the US Food and Drug Administration (FDA) has approved ALK’s ODACTRA® tablet for use in young children with house dust mite (HDM) allergy. ODACTRA® is now indicated to treat HDM-induced allergic rhinitis, with or without conjunctivitis, in children aged five through 11, in addition to patients aged 12 through 65. ODACTRA® is an allergy immunotherapy (AIT) tablet which dissolves under the tongue and helps patients reduce their allergy symptoms and t

GlobeNewswire 2 months ago

AKBLF
Annual General Meeting in ALK-Abelló A/S on 13 March 2025

ALK (ALKB:DC / OMX: ALK B / AKBLF): The Annual General Meeting of ALK-Abelló A/S will take place on Thursday, 13 March 2025 at 4:00 PM (CET) at ALK-Abelló A/S, Bøge Allé 1, 2970 Hørsholm, Denmark. The agenda of the meeting including the complete proposals from the Board of Directors to the AGM is attached. ALK-Abelló A/S For further information please contact: Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525 Media: Maiken Riise Andersen, tel. +45 5054 1434 About ALKALK

GlobeNewswire 2 months ago

AKBLF
Annual report 2024: ALK delivers 15% sales growth with profits up 65%

ALK’s (ALKB:DC / OMX: ALK B / AKBLF) Board of Directors has approved the 2024 annual report. Following a robust performance in Q4, full-year results were in line with the latest outlook and represent the best results in the history of the company. ALK expects to continue its growth trajectory and earnings improvement in 2025. Q4 2024 highlights (Comparative figures are shown in brackets. Growth rates are stated in local currencies, unless otherwise indicated) Revenue increased by 11% to DKK 1,49

GlobeNewswire 2 months ago

AKBLF
Invitation to the presentation of ALK’s annual report 2024 on Wednesday, 19 February 2025

ALK (ALKB:DC / OMX: ALK B / AKBLF) will publish its annual report for 2024 in the morning on Wednesday, 19 February 2025. Later on the same day, the company will host a presentation for investors and analysts at 1:30 p.m. CET, where ALK’s management will comment on the results and outlook and be available for questions. ALK will be represented by Peter Halling, President & CEO, Claus Steensen Sølje, CFO and Per Plotnikof, VP, Head of IR. Live audio webcast The meeting will be audio webcasted liv

GlobeNewswire 2 months ago

AKBLF
ALK’s house dust mite tablet (ACARIZAX®) now recommended by NICE for use in the UK health system

ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the National Institute for Health and Care Excellence (NICE) has recommended the use of ACARIZAX® for the treatment of persistent, moderate to severe house dust mite allergic rhinitis in adults and adolescents. The recommendation paves the way for patients to gain access to ACARIZAX® through the National Health Service (NHS) systems in England, Wales, and Northern Ireland, now making it eligible for general reimbursement. ACARIZAX® is the f

GlobeNewswire 2 months ago

AKBLF
3 Stocks Estimated To Be Trading At Discounts Of 26% To 44%

As global markets experience fluctuations with cooling inflation and strong bank earnings propelling U.S. stocks higher, investors are increasingly focused on identifying opportunities amidst these shifting conditions. In this environment, finding undervalued stocks can be a compelling strategy, as they may offer potential value when market sentiment is volatile and certain sectors outperform others.

Simply Wall St. 3 months ago

AKBLF

METSA.HE

METSB.HE
3 Stocks That May Be Trading Below Estimated Value

In the current climate, global markets are experiencing volatility with U.S. stocks facing declines due to cautious Federal Reserve commentary and political uncertainties, while European and Asian indices also reflect investor apprehension over interest rate outlooks. Amid these fluctuations, identifying stocks that may be trading below their estimated value can offer potential opportunities for investors seeking to capitalize on market inefficiencies. A good stock in this context is one that...

Simply Wall St. 4 months ago

AKBLF

CSCCF
ALK – Financial calendar for the 2025 financial year

2025 financial calendar for ALK (ALKB:DC / OMX: ALK B / AKBLF): 22 January 2025: Silent period 19 February 2025: Annual report 2024 13 March 2025 at 4.00 p.m.: Annual General Meeting to be held at ALK Bøge Allé 1 2970 Hørsholm, Denmark Written requests to have specific business transacted at the AGM will be included in the agenda if received by the company on 29 January 2025 at the latest (may be emailed to investor@alk.net) 8 April 2025: Silent period 6 May 2025: Three-month interim report (Q1)

GlobeNewswire 4 months ago

AKBLF
Positive results advance peanut tablet to phase II development

ALK’s peanut tablet shown to be safe and tolerable across multiple doses.Development now advances to phase II for dose finding and efficacy. First patients in phase II to receive first doses imminently. Trial expected to complete in 2026. ALK (ALKB:DC / OMX: ALK B) today announced positive interim results from its phase I/II clinical trial (named ‘ALLIANCE’) for its investigational sublingual immunotherapy (‘SLIT’) tablet for the treatment of peanut allergy. This part of the trial, which involve

GlobeNewswire 4 months ago

AKBLF
ACARIZAX® approved in Europe for treatment of young children

ALK (ALKB:DC / OMX: ALK B) today announced that its European regulatory filing for ACARIZAX® (house dust mite sublingual allergy immunotherapy tablet) in young children aged five to 11 has been approved by the health authorities in 21 EU countries via a type II variation procedure. The first market introductions, including in ALK’s largest market, Germany, are expected to follow over the coming months. The data that formed the basis for the approval includes results from the largest-ever paediat

GlobeNewswire 4 months ago

AKBLF
ALK’s pivotal phase 3 trial in children published in reputable scientific journal

The reputable scientific journal, The Lancet Regional Health – Europe, has published robust results from ALK’s house dust mite sublingual allergy immunotherapy tablet (SLIT-tablet) phase 3 children trial, MT-12, evaluating the efficacy and safety in children (5-11 years) with house dust mite allergic rhinitis.1 With the acceptance for publication, ALK’s MT-12 phase 3 trial has been evaluated by the journal for its methodology, relevance, and clinical implications. This scrutiny helps ensure that

GlobeNewswire 5 months ago

AKBLF

Performance Overview

Return	ALKBC.XC	OMX Copenhagen 25 Index (^OMXC25)
YTD	-11.10%	-10.09%
1-Year	+16.72%	-15.86%
3-Year	-78.69%	-8.90%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

ALK-Abelló A/S (ALKBC.XC)

ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians

ALK enters into neffy® co-promotion agreement in the USA

Invitation to the presentation of ALK’s first quarter 2025 results on Tuesday, 6 May 2025

ITULAZAX® tree pollen tablet approved for treatment of children in Europe

Grant of share-based long-term incentive instruments to members of the Board of Management and key employees

Annual General Meeting in ALK-Abelló A/S held on 13 March 2025

ACARIZAX® approved in Canada for treatment of young children

Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff

U.S. FDA Approves Label Expansion for ALK's ODACTRA® (House Dust Mite Allergen Tablet) for Sublingual Use as Immunotherapy to Now Include Children with House Dust Mite Allergy

FDA approves ODACTRA® for the treatment of house dust mite allergy in young children

Annual General Meeting in ALK-Abelló A/S on 13 March 2025

Annual report 2024: ALK delivers 15% sales growth with profits up 65%

Invitation to the presentation of ALK’s annual report 2024 on Wednesday, 19 February 2025

ALK’s house dust mite tablet (ACARIZAX®) now recommended by NICE for use in the UK health system

3 Stocks Estimated To Be Trading At Discounts Of 26% To 44%

3 Stocks That May Be Trading Below Estimated Value

ALK – Financial calendar for the 2025 financial year

Positive results advance peanut tablet to phase II development

ACARIZAX® approved in Europe for treatment of young children

ALK’s pivotal phase 3 trial in children published in reputable scientific journal

Performance Overview